Phaseline

Companies › Jaguar Gene Therapy

Jaguar Gene Therapy: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Other; next expected readout Jun 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JAG201
Adeno-associated virus 2/9 expressing a miniature version of the human SHANK3 gene (AAV2/9
SHANK3Phase 1SHANK3 HaploinsufficiencyJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06662188JAG201Phase 1SHANK3 HaploinsufficiencyOtherJun 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

SHANK3 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.